Literature DB >> 23736314

Effects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine abusers.

Sandra D Comer1, Shanthi Mogali, Phillip A Saccone, Paula Askalsky, Diana Martinez, Ellen A Walker, Jermaine D Jones, Suzanne K Vosburg, Ziva D Cooper, Perrine Roux, Maria A Sullivan, Jeanne M Manubay, Eric Rubin, Abigail Pines, Emily L Berkower, Margaret Haney, Richard W Foltin.   

Abstract

Despite the prevalent worldwide abuse of stimulants, such as amphetamines and cocaine, no medications are currently approved for treating this serious public health problem. Both preclinical and clinical studies suggest that the opioid antagonist naltrexone (NTX) is effective in reducing the abuse liability of amphetamine, raising the question of whether similar positive findings would be obtained for cocaine. The purpose of this study was to evaluate the ability of oral NTX to alter the cardiovascular and subjective effects of D-amphetamine (D-AMPH) and cocaine (COC). Non-treatment-seeking COC users (N=12) completed this 3-week inpatient, randomized, crossover study. Participants received 0, 12.5, or 50 mg oral NTX 60 min before active or placebo stimulant administration during 10 separate laboratory sessions. Oral AMPH (0, 10, and 20 mg; or all placebo) was administered in ascending order within a laboratory session using a 60-min interdose interval. Smoked COC (0, 12.5, 25, and 50 mg; or all placebo) was administered in ascending order within a laboratory session using a 14-min interdose interval. Active COC and AMPH produced dose-related increases in cardiovascular function that were of comparable magnitude. In contrast, COC, but not AMPH, produced dose-related increases in several subjective measures of positive drug effect (eg, high, liking, and willingness to pay for the drug). NTX did not alter the cardiovascular effects of AMPH or COC. NTX also did not alter positive subjective ratings after COC administration, but it did significantly reduce ratings of craving for COC and tobacco during COC sessions. These results show that (1) oral AMPH produces minimal abuse-related subjective responses in COC smokers, and (2) NTX reduces craving for COC and tobacco during COC sessions. Future studies should continue to evaluate NTX as a potential anti-craving medication for COC dependence.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23736314      PMCID: PMC3799062          DOI: 10.1038/npp.2013.143

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  49 in total

Review 1.  Psychostimulant treatment of cocaine dependence.

Authors:  John J Mariani; Frances R Levin
Journal:  Psychiatr Clin North Am       Date:  2012-04-26

2.  Naltrexone and relapse prevention treatment for cocaine-dependent patients.

Authors:  J M Schmitz; A L Stotts; H M Rhoades; J Grabowski
Journal:  Addict Behav       Date:  2001 Mar-Apr       Impact factor: 3.913

3.  Naltrexone decreases D-amphetamine and ethanol self-administration in rhesus monkeys.

Authors:  Corina Jimenez-Gomez; Gail Winger; Reginald L Dean; Daniel R Deaver; James H Woods
Journal:  Behav Pharmacol       Date:  2011-02       Impact factor: 2.293

4.  Naltrexone alteration of acute smoking response in nicotine-dependent subjects.

Authors:  A C King; P J Meyer
Journal:  Pharmacol Biochem Behav       Date:  2000-07       Impact factor: 3.533

5.  Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial.

Authors:  Anthony DeFulio; Jeffrey J Everly; Jeannie-Marie S Leoutsakos; Annie Umbricht; Michael Fingerhood; George E Bigelow; Kenneth Silverman
Journal:  Drug Alcohol Depend       Date:  2011-07-22       Impact factor: 4.492

6.  Reinforcing effects of d-amphetamine: influence of novel ratios on a progressive-ratio schedule.

Authors:  Rajkumar J Sevak; William W Stoops; Paul E A Glaser; Lon R Hays; Craig R Rush
Journal:  Behav Pharmacol       Date:  2010-12       Impact factor: 2.293

7.  The effects of escalating doses of smoked cocaine in humans.

Authors:  Richard W Foltin; Amie S Ward; Margaret Haney; Carl L Hart; Eric D Collins
Journal:  Drug Alcohol Depend       Date:  2003-05-21       Impact factor: 4.492

8.  The effect of naltrexone on amphetamine-induced conditioned place preference and locomotor behaviour in the rat.

Authors:  Jenny Häggkvist; Sara Lindholm; Johan Franck
Journal:  Addict Biol       Date:  2009-03-05       Impact factor: 4.280

9.  Tobacco, cocaine, and heroin: Craving and use during daily life.

Authors:  David H Epstein; Gina F Marrone; Stephen J Heishman; John Schmittner; Kenzie L Preston
Journal:  Addict Behav       Date:  2009-11-12       Impact factor: 3.913

10.  High-dose naltrexone therapy for cocaine-alcohol dependence.

Authors:  Joy M Schmitz; Jan A Lindsay; Charles E Green; David V Herin; Angela L Stotts; F Gerard Moeller
Journal:  Am J Addict       Date:  2009 Sep-Oct
View more
  31 in total

1.  Amphetamine potency varies with dopamine uptake rate across striatal subregions.

Authors:  Cody A Siciliano; Erin S Calipari; Sara R Jones
Journal:  J Neurochem       Date:  2014-07-30       Impact factor: 5.372

Review 2.  Agonist Medications for the Treatment of Cocaine Use Disorder.

Authors:  S Stevens Negus; Jack Henningfield
Journal:  Neuropsychopharmacology       Date:  2014-12-11       Impact factor: 7.853

Review 3.  Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature.

Authors:  Kelly E Courtney; Lara A Ray
Journal:  Drug Alcohol Depend       Date:  2014-08-17       Impact factor: 4.492

4.  Pharmacotherapeutic strategies for treating cocaine use disorder-what do we have to offer?

Authors:  Laura Brandt; Thomas Chao; Sandra D Comer; Frances R Levin
Journal:  Addiction       Date:  2020-09-28       Impact factor: 6.526

5.  Naltrexone and bupropion, alone or combined, do not alter the reinforcing effects of intranasal methamphetamine.

Authors:  William W Stoops; Erika Pike; Lon R Hays; Paul E Glaser; Craig R Rush
Journal:  Pharmacol Biochem Behav       Date:  2014-11-29       Impact factor: 3.533

6.  Sex differences in acute hormonal and subjective response to naltrexone: The impact of menstrual cycle phase.

Authors:  Daniel J O Roche; Andrea C King
Journal:  Psychoneuroendocrinology       Date:  2014-10-30       Impact factor: 4.905

Review 7.  Monoamine transporter inhibitors and substrates as treatments for stimulant abuse.

Authors:  Leonard L Howell; S Stevens Negus
Journal:  Adv Pharmacol       Date:  2014

8.  Need and utility of a polyethylene glycol marker to ensure against urine falsification among heroin users.

Authors:  Jermaine D Jones; Jared J Atchison; Gabriela Madera; Verena E Metz; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2015-05-27       Impact factor: 4.492

9.  Separate and combined impact of acute naltrexone and alprazolam on subjective and physiological effects of oral d-amphetamine in stimulant users.

Authors:  Katherine R Marks; Joshua A Lile; William W Stoops; Craig R Rush
Journal:  Psychopharmacology (Berl)       Date:  2014-01-25       Impact factor: 4.530

10.  Safety and tolerability of intranasal cocaine during phendimetrazine maintenance.

Authors:  William W Stoops; Justin C Strickland; Lon R Hays; Abner O Rayapati; Joshua A Lile; Craig R Rush
Journal:  Psychopharmacology (Berl)       Date:  2016-03-01       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.